Tirzepatide is a dual agonist medication for the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. Developed by Eli Lilly and Company, it is available as a once-weekly subcutaneous injection. In the United States, Tirzepatide is sold under the brand name Mounjaro for treating type 2 diabetes in adults and children 10 years and older, and as Zepbound for weight loss, weight management, and treatment of obstructive sleep apnea in adults. Tirzepatide works by mimicking the GLP-1 and GIP hormones, stimulating insulin release, reducing glucagon secretion, slowing gastric emptying, suppressing appetite, and increasing the feeling of fullness.
Tirzepatide was initially in shortage due to high demand after Mounjaro's FDA approval in May 2022, but the FDA has determined that the shortage is resolved as of December 2024. As of March 19, 2025, pharmacies are no longer allowed to compound tirzepatide. The list price for a month's supply of tirzepatide is approximately $1,079.77 for Mounjaro and $1,086.37 for Zepbound without insurance. Eli Lilly offers savings programs, potentially reducing the monthly cost to as low as $25 with insurance. Without insurance, the starting dose through Eli Lilly's online pharmacy is $349 a month, with subsequent doses costing $499 a month.